Clinical Trial Update: PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating PS-341 (bortezomib) in combination with carboplatin for platinum- and taxane-resistant recurrent ovarian cancer, primary peritoneal can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PS-341 (bortezomib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Ovarian Cancer, Primary Peritoneal Cancer | Phase 1 | Status: COMPLETED